SELLAS' AML Survival Win Sets Up Its FDA Push & Isomorphic Raises $5B

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
SELLAS reports median survival of 24.0 months with its vaccine versus 14.7 with investigator-chosen care in REGAL, a Phase 3 trial in later-remission AML; we unpack the filing stakes and topline limits. Isomorphic Labs raises $5 billion to move AI drug discovery toward human trials. We examine GSK's Nuvalent-derived Nelkarmi (neladalkib) approval for previously treated ALK-positive lung cancer and new details in the existing FDA rejection letter for Summit's ivonescimab. The roundup covers Beren's Lembaz (adrabetadex) in infantile-onset Niemann-Pick type C, Novartis' Cosentyx (secukinumab) in polymyalgia rheumatica, and Helus' investigational HLP003 depression results—with evidence limits and safety tradeoffs. Alex Mercer and Maya Patel host.
Episode information is provided by the publisher. Listening takes place on the publisher’s service.
Listen at the source ↗







